drugset
drugset / Trial / NCT03773666

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

NCT03773666 ↗

Phase 1 Completed 12 enrolled Dana-Farber Cancer Institute AstraZeneca · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying a new anti-cancer drug durvalumab (MEDI4736) with or without another new anti-cancer drug Oleclumab (MEDI9447) before surgery for bladder cancer. The drugs involved in this study are: * Durvalumab (MEDI4736) * Oleclumab (MEDI9447)

Timeline

Start
2019-02-20
Primary completion
2021-02-04
Completion
2021-08-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody — Intravenous
Subject Oleclumab Monoclonal antibody — Intravenous

Indications

urinary bladder carcinoma